Windward Bio Opens at $18.35 After Raising $175 Million
The Basel-based biotech firm priced its initial public offering at $17 per share on the Nasdaq.
By Mei Chen ·

Windward Bio, a biotechnology firm based in Basel, Switzerland, opened trading on the Nasdaq on Friday at $18.35 per share. The company had priced its initial public offering at $17 per share, a figure within the marketed range of $16 to $18. This opening price established a market valuation of $1.07 billion for the firm.
The company raised $175 million through the offering. Windward is developing antibody medicines for serious respiratory and dermatologic diseases. These conditions include asthma, chronic obstructive pulmonary disease, and atopic dermatitis. French drugmaker Sanofi agreed to purchase $50 million of shares and pre-funded warrants in a separate private placement.
Luca Santarelli serves as the company's chief executive officer. He previously led VectivBio and Therachon. VectivBio was sold for $1.2 billion, while Therachon was sold for $810 million.
The debut occurred while the wider initial public offering market faces challenges. An AI-driven tech selloff and higher-for-longer interest rates have weighed on activity. However, the biotech sector has seen a revival in activity this year. More than half a dozen biotech firms have gone public in New York since September.
Jeff Zell, a senior research analyst at IPO Boutique, noted that the biotech sector is sometimes not truly affected by the broader market during IPO lulls. He stated that large chunky orders in biotech order books and smaller transaction sizes make offerings more manageable and easier to complete for companies.
The company is backed by Novo Holdings. Shares have risen above the IPO price in their debut trading.
More Business · Consumer Watch · Report a business · Got a Story?






